Dermatology

This year, World Leprosy Day falls on Sunday 28th January. The occasion has been observed since 1954 and aims to raise awareness, providing more people…

Prof Girolomoni provided an overview of psoriasis, considering how patients are frequently affected by other comorbidities.

The oral session consisted of a talk on the 2-year efficacy and safety of guselkumab in the treatment of moderate-to-severe psoriasis from the Phase III VOYAGE 1 trial.

Prof Costanzo welcomed attendees to the symposium and outlined the agenda before explaining the autoimmune pathophysiology that underlies psoriasis.

Some types of chronic urticaria (CU) are associated with autoreactive immunoglobulin (Ig)E, as well as IgG. In the syndrome of autoimmune thyroid disease…

MY TREATMENT with isotretinoin was a long time coming. Having suffered for many years with severe acne, and with antibiotics only making a small dent in…

This symposium is focused on topical therapies in the treatment of psoriasis and the unmet clinical and patient quality of life needs.

Dermatologists today have more tools than ever at their disposal for managing psoriasis, including newer-generation biologics, which target molecular…